Nanobiotix (NBTX) Competitors $9.24 +0.25 (+2.83%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. JANX, EWTX, ARDX, HROW, SPRY, SDGR, AMPH, VERA, ABCL, and ETNBShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), AbCellera Biologics (ABCL), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors Janux Therapeutics Edgewise Therapeutics Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics AbCellera Biologics 89BIO Janux Therapeutics (NASDAQ:JANX) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership. Is JANX or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat Janux Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -11.48% -11.01% Nanobiotix N/A N/A N/A Which has more risk & volatility, JANX or NBTX? Janux Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Which has higher valuation and earnings, JANX or NBTX? Janux Therapeutics has higher earnings, but lower revenue than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10.59M130.79-$68.99M-$1.80-12.81Nanobiotix$39.18M11.31-$73.73MN/AN/A Do analysts rate JANX or NBTX? Janux Therapeutics presently has a consensus target price of $86.90, indicating a potential upside of 277.01%. Nanobiotix has a consensus target price of $8.00, indicating a potential downside of 13.42%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Janux Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor JANX or NBTX? In the previous week, Janux Therapeutics had 5 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Janux Therapeutics and 2 mentions for Nanobiotix. Janux Therapeutics' average media sentiment score of 1.45 beat Nanobiotix's score of 1.27 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in JANX or NBTX? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryJanux Therapeutics beats Nanobiotix on 11 of the 14 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$442.97M$2.79B$5.76B$9.84BDividend YieldN/A1.68%3.95%4.02%P/E RatioN/A22.8031.3126.63Price / Sales11.31737.59461.66121.17Price / CashN/A177.7737.7659.36Price / Book-6.126.1510.026.69Net Income-$73.73M$32.94M$3.27B$265.59M7 Day Performance-5.13%0.99%3.17%3.44%1 Month Performance38.95%1.70%4.36%1.12%1 Year Performance59.31%11.41%44.16%23.91% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix0.8081 of 5 stars$9.24+2.8%$8.00-13.4%+74.8%$442.97M$39.18M0.00100Positive NewsGap UpJANXJanux Therapeutics2.5497 of 5 stars$25.53+1.7%$91.89+259.9%-48.3%$1.51B$10.59M-14.1830News CoverageEWTXEdgewise Therapeutics2.3223 of 5 stars$14.00-1.1%$41.60+197.1%-26.9%$1.49BN/A-9.0360ARDXArdelyx4.1399 of 5 stars$5.81-2.7%$11.50+97.9%-0.5%$1.44B$386.15M-25.2690News CoveragePositive NewsInsider TradeHROWHarrow3.4433 of 5 stars$38.32-1.3%$64.67+68.8%-10.6%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.4031 of 5 stars$14.03-3.4%$31.00+121.0%-3.7%$1.44B$89.15M-28.6390SDGRSchrodinger2.8535 of 5 stars$20.05+3.5%$27.83+38.8%-4.0%$1.43B$207.54M-8.08790Positive NewsAMPHAmphastar Pharmaceuticals3.3959 of 5 stars$29.76-0.2%$31.50+5.8%-37.1%$1.39B$722.68M11.152,028News CoveragePositive NewsAnalyst ForecastVERAVera Therapeutics3.8314 of 5 stars$21.80+1.2%$63.00+189.0%-41.5%$1.37BN/A-6.0940News CoveragePositive NewsABCLAbCellera Biologics2.2837 of 5 stars$4.67+1.7%$8.00+71.3%+66.7%$1.37B$28.83M-8.49500News CoverageGap UpETNB89BIO2.347 of 5 stars$9.44+2.3%$26.29+178.5%+2.2%$1.37BN/A-2.6140News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Janux Therapeutics Competitors Edgewise Therapeutics Competitors Ardelyx Competitors Harrow Competitors ARS Pharmaceuticals Competitors Schrodinger Competitors Amphastar Pharmaceuticals Competitors Vera Therapeutics Competitors AbCellera Biologics Competitors 89BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access